Giant cell arteritis;Maladie de horton

Revue du Praticien

Volumn 58, Issue 5, 2008, Pages 513-521

  Liozon, Éric ^b   Ly, Kim ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE F 18; INFLIXIMAB; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE ACETATE;

ACUTE PHASE RESPONSE; AORTA ANEURYSM; AORTA ARCH SYNDROME; AORTITIS; BLINDNESS; BLOOD VESSEL BIOPSY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DOPPLER ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; GIANT CELL ARTERITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; ISCHEMIC HEART DISEASE; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; TEMPORAL ARTERY; VISUAL IMPAIRMENT;

ADRENAL CORTEX HORMONES; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BIOPSY; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DAPSONE; FEMALE; FOLLOW-UP STUDIES; GIANT CELL ARTERITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENCE; TEMPORAL ARTERIES; TIME FACTORS; ULTRASONOGRAPHY, DOPPLER, DUPLEX;

EID: 41449097562     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Weyand CM, Goronzy JJ. Medium-and large-vessel vasculitis. N Engl J Med 2003;349:160-9.
2. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-71.
3. Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 2003;33:38-48.
4. Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999;42:311-7.
5. Liozon F. La maladie de Horton. Ann Med Interne 1989;140:122-41.
6. Knockaert DC, Vanneste Lj, Bobbaers HJ. Fever of unknown origin in elderly patients. J Am Geriatr Soc 1993;41:1187-92.
7. Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001;111:211-7.
8. Aiello P, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology 1993:4550-5.
9. Liu GT, Glaser JS, Schatz NJ, Smith JL. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology 1994;101:1779-85.
10. Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005;112:1098-103.
11. Caselli RJ, Hunder GG. Neurologic aspects of giant cell (temporal) arteritis. Rheum Dis Clin North Am 1993;19:941-53.
12. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995;122:502-7.
13. Evans JM, Bowles CA, Bjornsson J, Mullany CJ, Hunder GG. Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum 1994;37:1539-47.
14. Duhaut P, Berruyer M, Pinede L, et al. Anticardiolipin antibodies and giant cell arteritis: a prospective, multicenter case-control study. Groupe de recherche sur l'artérite à cellules géantes. Arthritis Rheum 1998;41:701-9.
15. Blockmans D, De Ceuninck L, Vandenschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study in 35 patients. Arthritis Rheum 2006;55:131-7.
16. Narvaez J, Bernad B, Roig-Vilaseca D, et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum 2007;37:13-9.
17. Hall JK, Volpe NJ, Galetta SL, Liu GT, Syed NA, Balcer LJ. The role of unilateral temporal artery biopsy. Ophthalmology 2003;110:543-8.
18. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.
19. Genereau T, Lortholary O, Pottier MA, et al. Temporal artery biopsy: a diagnostic tool for systemic necrotizing vasculitis. French Vasculitis Study Group. Arthritis Rheum 1999;42:2674-81.
20. Liozon E, Boutros-Toni F, Loustaudratti, Ly K, Soria P, Vidal E. Silent, or occult, giant cell (temporal) arteritis is associated with a strong inflammatory response and a benign short term course. J Rheumatol 2003;30:1272-6.
21. Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000;27:1484-91.
22. Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006;54:3310-8.
23. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004;50:1332-7.
24. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703-8.
25. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. A randomized trial. Ann Intern Med 2007;146:621-30.
26. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007;56:2789-97.
27. Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004;141:493-500.
28. Liozon F, Vidal E, Barrier JH. Dapsone in in giant cell arteritis treatment. Eur J Intern Med 1993;4:207-14.
29. Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 1996;100:193-6.
30. Uddhammar A, Eriksson AL, Nystrom L, Stenling R, Rantapaa-Dahlqvist S. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002;29:737-42.
31. Nuenninghoff DM, Hunder GG, Christiansen TJ, McClelland RL, Matteson EL. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003;48:3532-7.